SRS FOR BRAIN METASTASES
THE EVIDENCE THAT CHANGED STANDARD OF CARE
Twenty years ago, brain metastases patients received whole-brain radiation as standard, often causing significant cognitive decline. Randomised trial evidence has progressively established SRS as the preferred approach — preserving brain function while maintaining local tumour control.
analyticsAt a Glance
- check_circleSRS is now standard of care for 1–10 brain metastases with controlled systemic disease
- check_circleLocal control at 1 year: 85–95% for metastases ≤3 cm
- check_circleRTOG 9508 (2004): SRS + WBRT improved survival vs WBRT alone for single metastasis
- check_circleSRS alone now preferred over SRS + WBRT to preserve neurocognitive function
Why Brain Metastases Are the Most Important SRS Indication
Brain metastases develop in 20–40% of all cancer patients — from lung cancer (most common), breast cancer, melanoma, renal cell carcinoma, and colorectal cancer. They represent the most common brain tumour in adults and are a leading cause of cancer-related neurological morbidity. The management evolution over the last two decades is one of oncology's most significant quality-of-life improvements.
“The shift from whole-brain radiation to SRS for brain metastases is one of the most patient-meaningful advances in neuro-oncology over the past 20 years. It transformed a treatment that reliably caused cognitive decline into one that preserves it — without sacrificing tumour control.”
The Historical Standard: WBRT Alone
Until the 1990s, whole-brain radiation therapy (WBRT) was the only available intracranial treatment for brain metastases — given empirically to the entire brain regardless of metastasis number or location. WBRT reliably palliates symptoms but causes progressive cognitive decline, particularly in long-term survivors. For patients with controlled systemic disease who survived >6–12 months, WBRT-induced dementia was a significant quality-of-life burden.
The SRS Revolution: Precision Without Whole-Brain Exposure
SRS treats only the visible metastases — sparing the remaining brain from high-dose irradiation. For patients with 1–10 metastases, each ≤3–4 cm, SRS achieves equivalent or superior local control to WBRT for the treated lesions while preserving the surrounding brain from radiation damage. The cognitive benefit is transformative — particularly for patients surviving ≥6 months.
The Key Trials That Built the Evidence Base
The SRS evidence base for brain metastases was built through a sequence of landmark trials, each answering a specific clinical question about when SRS should be used and how it should be combined with other treatments.
RTOG 9508 (Andrews et al., Lancet 2004): SRS + WBRT vs WBRT Alone
333 patients with 1–3 brain metastases randomised to WBRT alone vs WBRT + SRS boost. Results: For patients with a single metastasis, SRS + WBRT improved median OS (6.5 vs 4.9 months; HR 0.64, p=0.04) and 1-year survival (28% vs 14%). No significant OS benefit for 2–3 metastases overall, but local control improved across all patients. This trial established SRS as a meaningful addition to standard WBRT for at least selected patients.
JROSG 99-1 (Aoyama et al., JAMA 2006): SRS Alone vs SRS + WBRT
132 patients with 1–4 brain metastases randomised to SRS alone vs SRS + WBRT. Results: No significant difference in overall survival (8.0 vs 7.5 months). Intracranial relapse was higher in SRS-alone arm (76.4% vs 46.8% at 1 year) — but salvage SRS for new metastases was feasible. Neurological function preservation was comparable. This trial provided the first randomised data supporting SRS alone as a viable strategy, leading to WBRT avoidance becoming standard for most patients.
EORTC 22952 (Kocher et al., JCO 2011): Surgery or SRS ± WBRT
359 patients with 1–3 metastases after surgery or SRS randomised to observation vs WBRT. Results: WBRT significantly reduced intracranial relapse but did NOT improve overall survival or duration of functional independence. Neurocognitive assessment showed WBRT caused cognitive decline. This trial provided strong evidence that adding WBRT to SRS did not improve survival or function — the first major trial to explicitly show WBRT's cognitive harm without survival benefit.
N107C / CEC.3 (Brown et al., Lancet Oncology 2016): SRS vs WBRT After Resection
194 patients post-surgical resection randomised to SRS to the resection cavity vs WBRT. Results: SRS was non-inferior for OS (12.2 vs 11.6 months). WBRT significantly worsened cognitive function at 6 months (decline in 85.7% vs 52.4% of evaluable patients). This trial specifically validated SRS to the surgical cavity as the preferred adjuvant treatment after brain metastasis resection, avoiding WBRT.
SRS Outcomes for Brain Metastases
Published local control, survival, and toxicity data from SRS brain metastases series.
SRS Local Control by Tumour Size
Local control defined as no progression at treated site. 1-year local control rates from large single-institution and pooled series.
- Local Control at 1 Year — Metastasis ≤1 cm92–98%
- Local Control at 1 Year — Metastasis 1–2 cm88–95%
- Local Control at 1 Year — Metastasis 2–3 cm80–90%
- Local Control at 1 Year — Metastasis >3 cm65–80%
- Symptomatic Radiation Necrosis Rate2–5%
Patient Selection for SRS in Brain Metastases
Current evidence-based and guideline-supported selection criteria for SRS vs alternative treatments.
| Factor | Favours SRS | Favours Alternative |
|---|---|---|
| Number of metastases | 1–10 (strong evidence 1–4; growing evidence 5–10) | >10 diffuse metastases — WBRT or systemic treatment |
| Size of metastases | Each lesion ≤3 cm (optimal); 3–4 cm (feasible) | >4 cm — surgery for mass effect; SRS for residual cavity |
| Performance status | ECOG 0–2; KPS ≥70 | ECOG 3–4; KPS <70 — supportive care discussion |
| Systemic disease control | Stable or responding systemic disease | Rapidly progressive systemic disease — prognosis may not justify intracranial treatment burden |
| Tumour histology | Most solid tumour histologies respond to SRS | SCLC with leptomeningeal disease — WBRT preferred; lymphoma — chemotherapy + WBRT |
| Symptomatic mass effect | No significant mass effect or oedema | Significant mass effect — surgery first; SRS to cavity post-operatively |
| Prior WBRT | Prior WBRT not a contraindication to SRS | No prior WBRT — WBRT still considered for diffuse leptomeningeal disease |
Explore the SRS Knowledge Base
Related SRS topics.
- What Is SRS and How Is It Different from Regular Radiation?
- SRS vs WBRT: Understanding the Neurocognitive Trade-Off
- Gamma Knife vs CyberKnife vs TrueBeam: How to Choose
- Brain Metastases — Condition Page
- Stereotactic Radiosurgery — Full Treatment Page
- PDT Combined with Immunotherapy: Science and China's Trials
Frequently Asked Questions
Common questions about SRS for brain metastases.
About the Evidence
I have 7 brain metastases. Is SRS still appropriate?
Yes. While the strongest randomised trial evidence for SRS is in patients with 1–4 metastases, observational data from large series consistently shows no survival difference between patients treated with SRS for 1–4 vs 5–10 brain metastases when systemic disease is controlled. ASCO and ASTRO guidelines support SRS for patients with "limited" brain metastases, with most expert centres extending SRS to 5–10 metastases in appropriate patients. Tumour volume (total burden) matters as much as number — five small 5 mm metastases is very different from five 3 cm metastases.
Will SRS permanently control my brain metastases?
SRS achieves local control (no growth at the treated site) in 85–95% of lesions at 1 year. However, approximately 30–50% of patients develop new brain metastases in untreated areas of the brain within the first year — the brain is not protected from new seeding the way WBRT would suppress it. New metastases are treated with additional SRS sessions. This is one reason SRS requires dedicated surveillance MRI every 6–8 weeks in the first year — to identify new lesions while they are small and treatable.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Brain Metastases Diagnosed? SRS May Be Your Best Treatment Option.
Upload your brain MRI, staging CT/PET, and oncology records. Our neuro-oncology team will assess whether SRS is appropriate and identify the most experienced centre for your specific brain metastases.
For informational purposes only. Brain metastases treatment decisions require multi-disciplinary neuro-oncology evaluation.